News

April 21, 2016April 21, 2016

Psoriasis Drug Trial’s ‘Database Soft Lock’ for Prurisol Announced by Cellceutix, Along with Company Updates

News

Cellceutix, a clinical stage biopharma that develops novel therapies for oncology, dermatology, anti-inflammatory, and antibiotic applications, is announcing the institution of a “Database Soft Lock” as well as key additional updates ... Read more

April 18, 2016April 18, 2016

Laser Therapy for Psoriasis Shows No Indication of Koebner Effect, According to Study

News

A recent research study demonstrated that people suffering from plaque psoriasis who received laser treatment did not show evidence of subsequent koebnerization. The research study, “Absence of Koebnerization Following Ablative and ... Read more

April 15, 2016

Psoriasis Patients at Higher Risk of Abdominal Aortic Aneurysm, Study Finds

News

New research reveals patients with psoriasis have a higher risk of suffering from abdominal aortic aneurysms (AAA), and the probability increases with the severity of the condition. The study, “Nationwide Study ... Read more

April 14, 2016

Phase 2 Study of Tofacitinib for Psoriasis Shows Specific Immune System Changes

News

A new study of the medication tofacitinib sheds light on how it may work to treat psoriasis. The research report, “Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized ... Read more

April 13, 2016

FDA Approves Eli Lilly’s Psoriasis Drug Taltz

News

The U.S. FDA recently approved a new drug, Taltz (ixekizumab), for the treatment of patients suffering from moderate-to-severe plaque psoriasis. Psoriasis is a long-lasting autoimmune disease characterized by patches of ... Read more